Data as of Dec 19
| -0.16 / -2.03%|
The 2 analysts offering 12-month price forecasts for PDL BioPharma Inc have a median target of 8.00, with a high estimate of 9.00 and a low estimate of 7.00. The median estimate represents a +3.36% increase from the last price of 7.74.
The current consensus among 2 polled investment analysts is to Hold stock in PDL BioPharma Inc. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.